These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27932982)

  • 1. Impact of
    Sun H; Qu Q; Chen ZF; Tan SL; Zhou HJ; Qu J; Chen H
    Front Pharmacol; 2016; 7():453. PubMed ID: 27932982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel.
    Wang T; Feng J; Zhou L; Zhao T; Zhang H; Shen H; Xu L; Sun L; Wu J; Li H; Yu L
    Endocr Metab Immune Disord Drug Targets; 2023; 23(2):196-204. PubMed ID: 35616671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
    Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
    [No Abstract]   [Full Text] [Related]  

  • 5. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention.
    Bai XF; Zhang YP; Zhou J; Wu Y; Li RF; Sun LZ; Ma QQ; Lou BW; Zhai BW; Liu MP; Cheng LL; Tong XN; Yuan ZY
    Thromb Res; 2018 Oct; 170():142-147. PubMed ID: 30193195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor is more effective than clopidogrel in carrier of nonfunctional
    Tekeste R; Garza G; Han S; Dong J
    AIMS Mol Sci; 2022; 9(2):66-78. PubMed ID: 35647265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.
    Hokimoto S; Mizobe M; Akasaka T; Arima Y; Kaikita K; Nakagawa K; Ogawa H
    Thromb Res; 2014 Apr; 133(4):599-605. PubMed ID: 24440142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI).
    Chen S; Zhang Y; Wang L; Geng Y; Gu J; Hao Q; Wang H; Qi P
    Med Sci Monit; 2017 Aug; 23():3824-3830. PubMed ID: 28783717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cytochrome P450 2C19 (CYP2C19) gene polymorphism and clopidogrel reactivity on long term prognosis of patients with coronary heart disease after PCI.
    Hu CY; Wang YL; Fan ZX; Sun XP; Wang S; Liu Z
    J Geriatr Cardiol; 2024 Jan; 21(1):90-103. PubMed ID: 38440340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
    Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
    Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
    Kaufmann J; Wellnhofer E; Kappert K; Urban D; Meyborg H; Hauptmann T; Müller A; Meixner M; Graf K; Fleck E; Stawowy P
    Coron Artery Dis; 2013 Jun; 24(4):312-20. PubMed ID: 23549485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of
    Yu D; Ma L; Zhou J; Li L; Yan W; Yu X
    Exp Ther Med; 2020 May; 19(5):3411-3418. PubMed ID: 32266041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention.
    Chen Y; Huang X; Tang Y; Xie Y; Zhang Y
    Int J Clin Exp Med; 2015; 8(6):9266-74. PubMed ID: 26309584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
    Hokimoto S; Akasaka T; Tabata N; Arima Y; Tsujita K; Sakamoto K; Kaikita K; Morita K; Kumagae N; Yamamoto E; Oniki K; Nakagawa K; Ogawa H
    Thromb Res; 2015 Jun; 135(6):1081-6. PubMed ID: 25891840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel.
    Chen YW; Liao YJ; Chang WC; Hsiao TH; Lin CH; Hsu CY; Liu TJ; Lee WL; Chen YM
    Front Cardiovasc Med; 2022; 9():994184. PubMed ID: 36072879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes.
    Kim H; Kim Y; Koh YS; Lee HK; Chae H; Jekarl DW; Lee JM; Shin WS; Kim TH
    Platelets; 2015; 26(2):148-53. PubMed ID: 24617511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
    Dong P; Yang X; Bian S
    Med Sci Monit; 2016 Dec; 22():4929-4936. PubMed ID: 27977637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.